The contribution of the EMT to the acquired resistance of NSCLC cells to EGFR-TKI is well-documented [5,8,38], and the upregulation of the EMT marker vimentin may drive AXL overexpression [8]. The gene discussed is AXL; the disease is non-small cell lung carcinoma.